Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY, US...
Enregistré dans:
Auteurs principaux: | Rawla P, Sunkara T, Raj JP |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9fc73e3d92d743d19ad5b6e9c02efeb7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
par: Byron P. Vaughn
Publié: (2021) -
ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
par: E. V. Voronina, et autres
Publié: (2018) -
Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study
par: Pedersen L, et autres
Publié: (2020) -
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
par: Javier P. Gisbert, et autres
Publié: (2021) -
Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos
par: Fluxá,Daniela, et autres
Publié: (2017)